KRAS and lung adenocarcinoma: The frequency of these driver mutations were identical to the previous report that analyzed unselected Japanese lung adenocarcinoma patients; EGFR mutation, KRAS mutation, ALK fusion, or HER2 mutation were identified in 67.7% (216/319) [26].